Drug Profile
Esonadogene imvoparvovec - Neurophth Therapeutics
Alternative Names: AAV2-ND4; AAV2-ND4 Gene Therapy; NFS-01; NR-082; rAAV2 ND4; Recombinant-adeno-associated-virus-NADH-dehydrogenase-subunit-4Latest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator Huazhong University of Science and Technology
- Developer Huazhong University of Science and Technology; Neurophth Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; NADH dehydrogenase subunit 4 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Leber's hereditary optic atrophy
Most Recent Events
- 19 Feb 2024 Neurophth Therapeutics completes enrolment in its phase I/II trial for Leber's hereditary optic atrophy in USA
- 21 Feb 2023 Neurophth Therapeutics announces intention to submit New Drug Application (NDA) to China National Medical Products Administration (NMPA) for Leber's hereditary optic atrophy
- 21 Feb 2023 Neurophth Therapeutics announces intention to launch Esonadogene imvoparvovec for Leber's hereditary optic atrophy in China